In the series CELLect Horizons, William Blair Biotechnology Research Analyst Sami Corwin, Ph.D., examines the cell and gene therapy platforms that are on the cusp of generating data that could transform the therapeutic landscape.
In a 2023 edition of this report, our analysts detailed in situ engineering of CAR-T therapies, which enables the creation of powerful, cancer killing immune cells within a patient's own body. In this edition of CELLect Horizons, we revisit the in vivo CAR-T landscape, summarizing the progress companies in the space have made over the last two years, detailing financing and business development in the field, and providing our perspectives on the field and its broader implications if the development of these modalities is successful.
For more information on William Blair’s healthcare equity research, contact us or your William Blair representative.